Biocon Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Biocon Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹55 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 96% of Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹15 is tangible; the rest is goodwill and other intangibles, often from buying other companies. Less tangible than 95% of Healthcare companies in India.
- Shareholder Slice Ratio: Share count rose 36% in 3 years, so each share's slice of the company became smaller. Dividends paid equalled 16% of profit over the same period. Bigger rise in share count than 95% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹372Over the last 3 years, every ₹100 of reported profit came with ₹372 of operating cash.
Higher than 95% of Healthcare companies in India.
Self-Funding Ratio
1.5×Over the last 3 years its own operating cash covered its investment spending (capex) 1.5 times.
Higher than 56% of Healthcare companies in India.
Cash Locked Ratio
₹21For every ₹100 of sales, ₹21 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹27 tied up three years earlier.
Less money tied up than 58% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
−₹1Sales grew 53% in 3 years, but profit fell: ₹1 less profit per ₹100 of extra sales.
Lower than 86% of Healthcare companies in India.
Asset Productivity Ratio
+53% / +22%In 3 years sales changed by +53% while total assets changed by +22%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.5×Debt due within a year is covered 0.5 times by its yearly operating cash.
Lower than 71% of Healthcare companies in India.
Cash Cushion Ratio
−21%Debt, after subtracting cash, equals 21% of its market value (net debt).
Lower than 91% of Healthcare companies in India.
Tangible Assets Ratio
55%Of every ₹100 the company owns, ₹55 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 96% of Healthcare companies in India.
Tangible Net Worth Ratio
15%Of every ₹100 of net worth, ₹15 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 95% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Biocon Limited owes ₹0.42 for every ₹1 it owns. Net profit fell 62% in the year to Mar 2026, and shrank 6% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
95.7Investors pay ₹95.7 for every ₹1 of Biocon Limited's yearly profit, higher than 90% of Healthcare companies in India.
P/B ratio
1.56The share price is 1.56 times Biocon Limited's book value per share, lower than 93% of Healthcare companies in India.
Market cap
₹52,981 CrThe total market value of all of Biocon Limited's shares at today's price (share price × number of shares), larger than 88% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹34,032 CrWhat Biocon Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹207.80Net worth divided by the number of shares. The share price of ₹323.50 is 1.6 times this, which is the P/B above.
Return on equity (ROE)
1.6%Biocon Limited earned 1.6% on its shareholders' money over the last year, lower than 90% of Healthcare companies in India.
Owes vs Owns
0.42×Biocon Limited owes ₹0.42 for every ₹1 it owns (low), higher than 66% of Healthcare companies in India.
Dividend yield
0.14%Biocon Limited pays 0.14% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in India.
Revenue growth
+11%Revenue rose 11% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Profit growth
-62%Net profit fell 62% in the year to Mar 2026, and shrank 6% a year on average over 3 years.
Profit margin
2.3%Biocon Limited keeps ₹2 of every ₹100 of revenue as net profit.
Cash quality
5.2×Cash from Biocon Limited's business was 5.2× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
1.8×Biocon Limited's operating profit covered its interest costs 1.8 times in the year to Mar 2026.
Cash vs debt
Net debtBiocon Limited had ₹11,392 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Biocon Limited's P/E ratio?
Investors pay ₹95.7 for every ₹1 of Biocon Limited's yearly profit, higher than 90% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Biocon Limited: ₹52,981 Cr ÷ ₹34,032 Cr (31 Mar 2026) = 1.6.
What is Biocon Limited's return on equity?
Biocon Limited earned 1.6% on its shareholders' money over the last year, lower than 90% of Healthcare companies in India.
How much does Biocon Limited owe compared with what it owns?
Biocon Limited owes ₹0.42 for every ₹1 it owns (low), higher than 66% of Healthcare companies in India.
Does Biocon Limited pay a dividend?
Yes. Biocon Limited pays 0.14% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in India.
Is Biocon Limited's revenue growing?
Revenue rose 11% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.